Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-07-30
2009-10-20
Kolker, Daniel E. (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S329000
Reexamination Certificate
active
07605133
ABSTRACT:
The present invention relates to drug screening methods and methods of preventing neural tissue damage caused by α-synuclein aggregation. These methods are especially useful in the design and development of inhibitors of Lewy body diseases and other synucleinopathies, and further useful in the treatment of such neurodegenerative diseases, particularly Parkinson's Disease.
REFERENCES:
patent: 6201104 (2001-03-01), MacDonald et al.
patent: 6780971 (2004-08-01), Wolozin et al.
patent: 2003/0044838 (2003-03-01), Turnbough
patent: WO-98/59050 (1998-12-01), None
patent: WO 99/36081 (1999-07-01), None
patent: WO-00/18917 (2000-04-01), None
patent: WO-00/20020 (2000-04-01), None
Souza et al (2000). FEBS Letters. 474,116-119.
Accession No. AAB67386 (1997). Appendix b, pp. 1-2.
Hashimoto, et al., “Oxidative Stress Induces Amyloid-like Aggregate Formation of NACP/Alphy-synuclein In Vitro,” Neuro Report, Mar. 1999, vol. 10, No. 4, pp. 717-721.
Ostretova-Golts, et al., “The A53T Alpha-Synuclein Mutation Increases Iron-Dependent Aggregation and Toxicity,” The Journal of Neuroscience, Aug. 15, 2000, vol. 20, No. 16, pp. 6043-6054.
Paik, et al., “Metal-Catalyzed Oxidation of Alpha-synuclein in the Presence of Copper (II) and Hydrogen Peroxide,” Archives of Biochem and Biophys., Jun. 2000, vol. 378, No. 2, pp. 269-277.
Hashimoto, et al., “Role of Cytochrome c as a Stimulator of Alpha-Synuclein Agregation I Lewy Body Disease,” Journal of Biol. Chem., Oct. 8, 1999, vol. 274, No. 41, pp. 28849-28852.
Database UniProt ′Online, Jan. 1, 1998 “Ylr269cp.” XP002358527 retrieved from EBI accession No. UNIPROT: 013550.
Snyder, et al., “Magneisum Inhibition of Alpha Synuclein Aggregation” Abstacts of the society for Neuroscience, 27(1):1445, 2001.
Lebowitz Michael S.
Ostretova-Golts Natalie
Wolozin Benjamin
Kolker Daniel E.
Panacea Pharmaceuticals, Inc.
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Isolated peptides to treat alpha-synuclein diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isolated peptides to treat alpha-synuclein diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isolated peptides to treat alpha-synuclein diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4066885